Anna Carolina Wright
Family · Lilburn, GANPI 1649767310
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (52.7%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Axsome Therapeutics, Inc. at 44.1% of the total. 2025 is the largest year on record at $24,045, more than ten times the $1,488 reported in 2021. Among family clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 713 payments — averaging $96.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$30K
- AbbVie$25K
- Johnson & Johnson$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$2K
- Otsuka America Pharmaceutical, Inc.$1K
- Teva Pharmaceuticals USA, Inc.$1K
- plus $7K from 28 others
What the payments were for
- Consulting fees$11,25016%
- Speaking & faculty fees$36,25053%
- Travel & lodging$4,6947%
- Food & beverage$16,31924%
- Education$2240%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Auvelity$28,915
- VRAYLAR$23,378
- SPRAVATO$1,376
- REXULTI$464
- ARISTADA$410
- INGREZZA$362
- CAPLYTA$352
- INVEGA SUSTENNA$244
- QELBREE$225
- AUSTEDO$130
- Fanapt$125
- ABILIFY MAINTENA$121
- Adzenys XR-ODT$118
- Azstarys$111
- Dyanavel XR$107
- ARISTADA INITIO$102
How this compares
$68,737 in reported general payments places this provider in the 95th percentile of 6,258 family providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 14 | $117,498 |
| RexultiBrexpiprazole | 36 | $51,609 |
| VraylarCariprazine Hcl | 30 | $43,995 |
| SpravatoEsketamine Hcl | 13 | $16,399 |
| Chlorpromazine Hcl | 43 | $3,158 |
| Clozapine | 11 | $1,835 |
| Ziprasidone Hcl | 16 | $1,560 |
| Quetiapine Fumarate | 103 | $1,459 |
| Clonazepam | 109 | $1,161 |
| Trazodone Hcl | 88 | $1,156 |
| Divalproex Sodium ErDivalproex Sodium | 12 | $1,088 |
| Duloxetine Hcl | 64 | $1,073 |
| Alprazolam | 161 | $1,015 |
| Gabapentin | 46 | $981 |
| Aripiprazole | 13 | $905 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Neurocrine Biosciences, Inc.Ingrezza | $845 | $117,49814 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $1,367 | $51,60936 claims |
| AbbVieVraylar | $25,036 | $43,99530 claims |
| Johnson & JohnsonSpravato | $2,658 | $16,39913 claims |
| Lilly USA, LLCOlanzapine | $23 | $49522 claims |
| Almatica Pharma LLCSertraline Hcl | $114 | $21544 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 6,258 family providers in Georgia.
Other family in Lilburn
- Allie McAllisterMarietta$299K
- Erin HenryLawrenceville$135K
- Trisha RomanPeachtree City$134K
- Lori ReedMarietta$106K
- Julia BranchCumming$102K
- Hannah BanachWaycross$85K
- Morgan GroothandEvans$81K
- Jessica FeehanCanton$51K
- Julia ThorneCanton$39K
- Stacey TatroeAtlanta$38K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.